RECRUITING

Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This phase II trial studies the side effects of hypofractionated radiation therapy in treating patients with soft tissue sarcomas prior to surgery. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects.

Official Title

Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort

Quick Facts

Study Start:2016-02-03
Study Completion:2026-02-03
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT02701153

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Histologically confirmed soft tissue sarcoma of the extremity/trunk
  2. * Intermediate or high grade sarcoma
  3. * Resectable primary lesion (patients with pre-existing metastasis will be included if their primary is still going to be resected)
  4. * Recurrent, any grade, no previous radiation therapy
  5. * Karnofsky performance status (KPS) \>= 70 or Eastern Cooperative Oncology Group (ECOG) 0 - 2
  6. * If a woman is of childbearing potential, a negative serum pregnancy test must be documented
  1. * Active treatment of a separate malignancy
  2. * History of prior irradiation to the area to be treated
  3. * Pre-operative chemotherapy (post-op acceptable)

Contacts and Locations

Study Contact

Jackie Hernandez
CONTACT
310-206-8477
jhernandez@mednet.ucla.edu

Principal Investigator

Anusa Kalbasi, MD
PRINCIPAL_INVESTIGATOR
UCLA / Jonsson Comprehensive Cancer Center

Study Locations (Sites)

UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095
United States

Collaborators and Investigators

Sponsor: Jonsson Comprehensive Cancer Center

  • Anusa Kalbasi, MD, PRINCIPAL_INVESTIGATOR, UCLA / Jonsson Comprehensive Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2016-02-03
Study Completion Date2026-02-03

Study Record Updates

Study Start Date2016-02-03
Study Completion Date2026-02-03

Terms related to this study

Additional Relevant MeSH Terms

  • Recurrent Adult Soft Tissue Sarcoma